传染科指南

订阅

MedSci主页 / 所有栏目 / 传染科指南

2022 JSC/JSTDM临床实践指南：替考拉宁治疗药物监测

2022-01-12 日本化疗学会 J Antimicrob Chemother

替考拉宁感染病病毒组MRSR

日本化疗学会(JSC)联合日本治疗药物监测学会(JSTDM)共同发布了替考拉宁治疗药物监测指南，由于替考拉宁不良反应风险较低，已广泛用于MRSR感染的治疗。

中文标题：

2022 JSC/JSTDM临床实践指南：替考拉宁治疗药物监测

英文标题：

Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

发布机构：

日本化疗学会

发布日期：

2022-01-12

简要介绍：

日本化疗学会(JSC)联合日本治疗药物监测学会(JSTDM)共同发布了替考拉宁治疗药物监测指南，由于替考拉宁不良反应风险较低，已广泛用于MRSR感染的治疗。本文主要针对替考拉宁治疗药物监测的相关内容提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 JSC／JSTDM临床实践指南：替考拉宁治疗药物监测.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d116d1c002320a90, title=2022 JSC/JSTDM临床实践指南：替考拉宁治疗药物监测, enTitle=Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring, guiderFrom=J Antimicrob Chemother, authorId=0, author=, summary=日本化疗学会(JSC)联合日本治疗药物监测学会(JSTDM)共同发布了替考拉宁治疗药物监测指南，由于替考拉宁不良反应风险较低，已广泛用于MRSR感染的治疗。, cover=https://img.medsci.cn/2022114/1642138522027_1608702.jpg, journalId=0, articlesId=null, associationId=2293, associationName=日本化疗学会, associationIntro=日本化疗学会(JSC,Japanese Society of Chemotherapy), copyright=0, guiderPublishedTime=Wed Jan 12 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">日本化疗学会(JSC)联合日本治疗药物监测学会(JSTDM)共同发布了替考拉宁治疗药物监测指南，由于替考拉宁不良反应风险较低，已广泛用于MRSR感染的治疗。本文主要针对替考拉宁治疗药物监测的相关内容提供指导建议。</span></p>, tagList=[TagDto(tagId=36852, tagName=替考拉宁), TagDto(tagId=117468, tagName=感染病病毒组), TagDto(tagId=121443, tagName=MRSR)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=5, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4080, appHits=21, showAppHits=0, pcHits=349, showPcHits=4058, likes=0, shares=0, comments=5, approvalStatus=1, publishedTime=Fri Jan 14 13:33:56 CST 2022, publishedTimeString=2022-01-12, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Fri Jan 14 13:45:22 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 23:18:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 JSC／JSTDM临床实践指南：替考拉宁治疗药物监测.pdf)])
2022 JSC／JSTDM临床实践指南：替考拉宁治疗药物监测.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1204720, encodeId=889f1204e2067, content=学习了佩服, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:39:28 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186760, encodeId=97d51186e60a7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 11:18:35 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185052, encodeId=b0af1185052c9, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6c45311937, createdName=1488c538m41暂无昵称, createdTime=Mon Jan 17 06:44:54 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184460, encodeId=b62611844605a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 15 07:22:27 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
    2022-03-21 ms6903418467290158

    学习了佩服

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1204720, encodeId=889f1204e2067, content=学习了佩服, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:39:28 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186760, encodeId=97d51186e60a7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 11:18:35 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185052, encodeId=b0af1185052c9, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6c45311937, createdName=1488c538m41暂无昵称, createdTime=Mon Jan 17 06:44:54 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184460, encodeId=b62611844605a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 15 07:22:27 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
    2022-01-21 wjl066452

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1204720, encodeId=889f1204e2067, content=学习了佩服, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:39:28 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186760, encodeId=97d51186e60a7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 11:18:35 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185052, encodeId=b0af1185052c9, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6c45311937, createdName=1488c538m41暂无昵称, createdTime=Mon Jan 17 06:44:54 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184460, encodeId=b62611844605a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 15 07:22:27 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
    2022-01-17 1488c538m41暂无昵称

    学习到了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1204720, encodeId=889f1204e2067, content=学习了佩服, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:39:28 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186760, encodeId=97d51186e60a7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 11:18:35 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185052, encodeId=b0af1185052c9, content=学习到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6c45311937, createdName=1488c538m41暂无昵称, createdTime=Mon Jan 17 06:44:54 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184460, encodeId=b62611844605a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Jan 15 07:22:27 CST 2022, time=2022-01-15, status=1, ipAttribution=)]
    2022-01-15 微探

    学习学习

    0

相关指南

2016 替考拉宁临床应用剂量专家共识

替考拉宁临床应用剂量专家共识组 · 2016-07-01